A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Treatment Action Group: Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendation
Today, Treatment Action Group (TAG) released a new resource, Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendation, to spark and support ongoing advocacy on TB R&D. Built upon over a decade of data from tracking funding resources, this new policy brief seeks to inform advocates and policymakers on key issues in TB R&D funding, including:
- The rise of drug-resistant TB as a critical global health security issue that requires new tools and strategies;
- The importance of U.S. government funding in past successes and in the future of innovative tests, treatments, and vaccines for TB;
- How inflation has eroded years of flat funding for TB R&D; and
- Recommendations on how to increase U.S. government funding for a more robust pipeline to combat TB.
To read and download the policy brief, click here.
Recent News and Announcements
With support from the Firland Foundation, RESIST-TB investigated mechanisms for accessing drugs prior to regulatory approval and surveyed key providers and advocates on their experience attempting to gain access to new TB drugs through compassionate use or similar pre-approval mechanisms. The findings from this project are detailed in this report, “Monitoring Compassionate Use of New […]
Update: The link to download Dr. Carole Mitnick’s presentation can be found here. A recording of the presentation will be made available shortly. Join us on Thursday, June 23rd from 9-10 EDT (15-16 CEST) for a webinar entitled “endTB Clinical Trial: Evaluating Newly approved Drugs for Multidrug-Resistant TB.” This webinar will provide an update on the design, study […]
This April the co-facilitators leading negotiations for the 2016 United Nations High-Level Meeting on Ending AIDS, the UN Permanent Representatives of Switzerland and Zambia, released the Zero Draft Political Declaration. The Zero Draft contains commitments which aim to end AIDS and TB epidemics by 2030, and will be negotiated and finalized by governments leading up to […]
In April 2016 the International Union Against Tuberculosis and Lung Disease and its affiliate Vital Strategies, announced that the STREAM Stage 2 clinical study has begun enrolling patients in Mongolia. This is the first phase III clinical trial to test the effectiveness of bedaquiline within a shortened MDR-TB treatment regimen. The STREAM Stage 2 study protocol […]
During the month of March, Stop TB partnership works to push the issue of TB higher on the agendas of decision makers, stakeholders, governments, programs, partners and communities. This year Stop TB Partnership aims to make not only March 24th, but the whole month of March especially impactful. To learn more about World TB day and […]